摘要
2024年美国临床肿瘤学会泌尿生殖肿瘤年会(ASCO-CU)报道了局限期前列腺癌领域有关剂量提升、疗程缩短等根治性放疗的优化、术后短疗程放疗的挑战,以及放疗技术的迭代等多方面研究进展。本文对其中重要研究进行解读和点评,以期为全面认识放疗技术的发展,尤其是立体定向放射治疗(SBRT)在局限期前列腺癌中的应用提供帮助。
The 2024 American Society of Clinical Oncology Genitourinary(ASCO-GU)Cancers Symposium presented the latest research advancements in dose escalation and hypofractionation of radical radiotherapy(RT),the challenges associated with post-operative hypofractionated or ultrahypofractionated RT,and the technical developments in RT for prostate cancer.This article aims to interpret and review these significant studies,providing a comprehensive understanding of RT technical advancements,particularly focusing on the application of stereotactic body radiation therapy(SBRT)in localized prostate cancer.
作者
刘洋
何立儒
Liu Yang;He Liru(Department of Radiation Oncology,State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2024年第4期258-260,共3页
Chinese Journal of Urology
关键词
前列腺癌
研究进展
立体定向放射治疗
Prostate cancer
Research progress
Stereotactic body radiation therapy
